Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Condition:   Non-syndromic Retinitis Pigmentosa Intervention:   Combination Product: Gene therapy: GS030-DP AND Medical device: GS030-MD Sponsor:   GenSight Biologics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials